Talphera (TLPH) Assets Average (2011 - 2026)
Talphera (TLPH) posted Assets Average of $28.5 million for Q2 2026, down 4.87% on a QoQ basis from $29.9 million in Q1 2026, and up 80.77% year-over-year from $15.8 million in Q2 2025.
Analysis
Talphera (TLPH) Assets Average (2011 - 2026) Analysis & Trends
Talphera has reported Assets Average for 16 years, with the latest figure at $28.5 million in Q2 2026.
- On a quarterly basis, Assets Average rose 80.77% year-over-year to $28.5 million in Q2 2026; TTM through Jun 2026 was $28.5 million, a 80.77% increase from a year earlier, with the FY2025 full-year figure at $24.0 million, up 24.14% from the prior year.
- Assets Average was $28.5 million for Q2 2026 at Talphera, down from $29.9 million in the prior quarter.
- The five-year high for Assets Average was $74.9 million in Q1 2022, with the low at $15.8 million in Q2 2025.
- Average Assets Average over 5 years is $32.2 million, with a median of $25.7 million recorded in 2024.
- The sharpest annual moves came in 2023 and 2026: Assets Average plunged 65.64% in 2023, then soared 80.77% in 2026.
- Over 5 years, Assets Average stood at $47.9 million in 2022, then plunged by 54.43% to $21.8 million in 2023, then declined by 10.09% to $19.6 million in 2024, then surged by 54.04% to $30.2 million in 2025, then declined by 5.79% to $28.5 million in 2026.
- The last three Assets Average figures came in at $28.5 million (Q2 2026), $29.9 million (Q1 2026), and $30.2 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 94.07 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 52.82 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 26.95 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 41.30 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 11.22 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 5.34 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 30.78 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 5.51 Bn |
| 10 | Talphera | 92.90 Mn | 92.90 Mn | - | 28.48 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 28.48 Mn |
| Mar 31, 2026 | 29.94 Mn |
| Dec 31, 2025 | 30.23 Mn |
| Sep 30, 2025 | 23.63 Mn |
| Jun 30, 2025 | 15.76 Mn |
| Mar 31, 2025 | 16.62 Mn |
| Dec 31, 2024 | 19.63 Mn |
| Sep 30, 2024 | 22.94 Mn |
| Jun 30, 2024 | 26.81 Mn |
| Mar 31, 2024 | 24.58 Mn |
| Dec 31, 2023 | 21.83 Mn |
| Sep 30, 2023 | 20.49 Mn |
| Jun 30, 2023 | 22.01 Mn |
| Mar 31, 2023 | 36.89 Mn |
| Dec 31, 2022 | 47.90 Mn |
| Sep 30, 2022 | 52.22 Mn |
| Jun 30, 2022 | 64.05 Mn |
| Mar 31, 2022 | 74.93 Mn |
| Dec 31, 2021 | 75.08 Mn |
| Sep 30, 2021 | 75.92 Mn |